US$ 25.20
retatrutide eli lilly press release 2024 2025 stock jumps on Phase 3 weight loss results Lilly's triple agonist delivers up
Description
It works by stimulating insulin secretion, which helps lower blood sugar when glucose levels are high

The EVOKE and EVOKE + trials are supported by robust preclinical evidence demonstrating GLP-1RA benefits in neurodegeneration and cognitive enhancement in T2DM patients (Akimoto et al., 2020

But what makes Reta even more interesting is that she improves metabolic health far beyond the scale reducing liver fat, inflammation, and insulin resistance

JAMA 318: 14601470, 2017
